尼達尼布
參考文獻

↑  Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double- blind, randomised controlled trial. Lancet Oncol 2014;15:143–55.
1 2  Selman M, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-51.
↑   Hilberg F., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-4782.
↑  Bergers G, et al. Angiogenesis: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
↑  Folkman J. Clinical Applications of Research on Angiogenesis. N Engl J Med 1995;333:1757–1763.
↑  Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
↑  Hilberg F, Roth GJ, Krssak M, et al. BIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res 2008;68:4774-82.
↑  Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
↑  Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in psychology and medicine. Genes Dev 2008;22:1276-312.
↑  Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-573.
↑  Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003;36:49-59.
↑  Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
↑  Hilberg F., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-4782.
↑  Wollin L., et al. Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis. J Pharmacol Exp Ther 2014;349:209–220.
↑  Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME- Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143–55.
↑  Richeldi L, et al. Design of the INPULSISTM Trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 2014 Jul; 108 (7):1023-30. DOI: 10.1016/j.rmed.2014.04.011.
↑  Richeldi, L., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine 2014 May; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584.
↑  Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02149108?term=nintedanib+colorectal&rank=2 （页面存档备份，存于） [Last Accessed May 2015].
↑  du Bois A, et al. AGO-OVAR 12/LUME-Ovar. Presented at ESGO 2013.
↑  Nintedanib (BIBF 1120) in Mesothelioma. Available at: http://clinicaltrials.gov/ct2/show/NCT01907100?term=nintedanib+mesothelioma&rank=1 （页面存档备份，存于） [Last Accessed May 2015].
↑  Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. Available at: http://clinicaltrials.gov/ct2/show/NCT01024920?term=nintedanib+renal&rank=1 （页面存档备份，存于） [Last Accessed May 2015].
↑  Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Available at: http://clinicaltrials.gov/show/NCT01004003 （页面存档备份，存于） [Last Accessed May 2015].